What can the broader U.S. tech sector learn from the way you apply generative AI to clinical trials?
The single most important lesson is that generative AI is only as good as its training data. Medidata’s algorithms sit on more than 36,000 fully adjudicated clinical trials. This history of trials creates an unrivalled corpus of operational information measuring what has worked and not worked across a wide variety of therapeutic areas as well as structured, patient-level information collected under strict regulatory standards. Because each trial follows a consistent protocol yet tests a novel therapy, the dataset captures both innovation and repeatability, giving the models rich historical context without noisy “real-world” gaps.
For technology companies outside life sciences, it's becoming increasingly important to invest early in a proprietary, domain-specific dataset that’s clean, deep, and broad. With that foundation, AI can move beyond experimentation and become an engine for redesigning legacy processes — in our case, helping sponsors run the “36,001st” trial far more efficiently than trials 1 through 36,000.
Why is the figure of 36,000 prior trials so critical when training your AI?
This amount of trials is orders of magnitude larger than anything a single pharmaceutical company, contract research organisation, or regulator could assemble. Those trials span every therapeutic area, every major geography, and study size from 10-patient rare-disease investigations to 40,000-plus-volunteer vaccine programmes. That breadth ensures the model sees the full range of trial designs it may need to emulate or improve.
Equally important, each record is “regulation-grade” data—cleaned, queried and locked before submission to authorities. Unlike electronic health-records or web-scraped information, there are no missing dosing dates, duplicate patients, or ambiguous endpoints. The combination of volume, variety and veracity is precisely what lets Medidata’s algorithms generate credible synthetic control arms and predictive study designs that regulators and sponsors can trust.
How does your AI platform differ from others, and what did you unveil in San Francisco?
First, we bring a decade of AI R&D to the table; that head start means our AI is already commercialised rather than experimental. Flagship tools such as Synthetic Control Arms use historical data to create “virtual twin” patients, sparing hundreds or even thousands of volunteers from placebo exposure while preserving statistical rigour.
Second, the platform is now completely cloud-native, driving our “AI Everywhere”strategy. Instead of standalone AI products that are sold separately, our machine-learning agents are woven into our standard platform user experiences, so all of our users get the uplift of AI assistants and insights inline with the way they complete their normal work routines. The San Francisco release extended that architecture with end-to-end data lineage, making every AI suggestion traceable from source record to on-screen prompt, a prerequisite for regulatory audit and for rapid feature deployment.
What has changed since the recent surge of interest in AI, and how much better are today’s models?
The most dramatic shift is willingness. Pharma has long been cautious about new technology, yet the global momentum behind AI now makes inaction riskier than adoption. That cultural change, more than any single technical milestone, is accelerating uptake across sponsors, sites, and regulators. Model quality is keeping pace: Competitors are still piloting concepts Medidata placed in production years ago thanks to our early start.
How do you balance the need for speed with the ethical obligations of clinical research?
In clinical development, we are dealing with human lives, sensitive health data and stringent privacy laws, so ethical guardrails are non-negotiable. Fortunately, the same regulators who certify drugs also oversee AI use, providing a built-in governor that prevents reckless acceleration. Regulators want therapies to reach patients faster, but only under transparent, auditable methods.
Medidata’s advantage is that its models are trained on consented, de-identified, meticulously curated data. That provenance supports trustworthy outputs such as synthetic control arms, which, by replacing placebo patients with historical data twins, actually reduces patient burden for the trial and helps solve some serious ethical conflicts. When algorithms are grounded in high-quality evidence and accompanied by clear validation, moving quickly does not mean cutting corners; it means eliminating unnecessary manual steps while keeping safety and privacy front-of-mind.
What does long-term success look like for Medidata?
Medidata’s mission is to “power smarter treatments and healthier people.” At any moment we are running more than 7,000 active trials, making us part of what I think of as a central nervous system for global clinical research.
Success, of course, lies in our customers inventing new molecules, but there’s also a lot more we can do as an industry to compress the timelines from first-in-human dosing to pharmacy shelf.
Today that path averages eight to ten years, with only one in ten candidates ultimately approved. By applying AI to optimize protocol design, detect futility early, and streamline data review, Medidata aims to raise the success rate and slice years off development timelines. Every month saved means patients receive life-saving therapies sooner, and every failed study halted promptly frees resources for more promising science. Optimizing this path through the research to a conclusion is where Medidata can really make a difference for the industry.
Can the impact of AI on drug development be overstated?
From a capability standpoint, no. Our expectation is that in the next year or two, we’ll uncover applications we have yet to imagine, making the five-to-ten-year horizon even more transformative. Generative models promise to redesign everything from molecule discovery to global trial logistics.
Yet the stakes are high: poor data or mis-specified models could send a programme down the wrong path at speed. Medidata’s meticulously curated dataset mitigates that risk, offering customers a way to innovate rapidly without gambling on unproven inputs. In other sectors, where data are messier, organisations should anticipate missteps; in regulated life sciences, trust and traceability are prerequisites for unleashing AI’s full potential.
Why launch the “From Dreamers to Disruptors” podcast, and what distinguishes its focus?
Our podcast aims to do two things: give Medidata a consistent platform to share thought leadership and insights, and spotlight individuals who’ve turned bold ideas into industry-changing realities. As a Medidata production, it also reflects our focus on pairing innovation with practical impact.
My background in early-stage ventures helps shape the guest list. Episodes feature entrepreneurs and scientists who’ve navigated the arduous path from concept to standard practice, offering candid lessons on regulatory hurdles, cultural adoption, and scaling. By chronicling that journey, the series aims to inspire the next wave of disruptors — while positioning Medidata at the center of the conversation.
